AQP4 and myelitis: Although the relapse activity and neurological sequelae in MOGAD patients are generally better than those in AQP4-Ab-positive NMOSD patients, some patients with MOGAD may experience severe irreversible neurological sequelae (for example, visual loss after ON or paraparesis after myelitis) after clinical attacks, regardless of appropriate administration of the acute treatment.